Abstract: A surface-treated steel material having cut edge corrosion resistance that is equal to or more than that of a chromate treatment without use of hexavalent chromium. The surface-treated steel material includes a coating film formed on a surface of a steel material through a plating layer that is obtained by immersing the steel material in a galvalume bath containing Mg. The coating film is formed using a coating composition containing a coating film-forming resin, a cross-linking agent, a predetermined vanadium compound, and trimagnesium phosphate; the vanadium compound is a compound satisfying a predetermined electrical conductivity; the content of the vanadium compound is restricted to a predetermined amount; the vanadium compound satisfies a predetermined pH; and the content of the trimagnesium phosphate is a predetermined amount.

Abstract: A surface-treated steel material includes a coating film formed on a surface of a steel material through a plating layer. The plating layer is obtained by immersing the steel material in a galvalume bath containing Mg. In the surface-treated steel material, the coating film is formed using a coating composition containing a coating film-forming resin, a cross-linking agent, a predetermined vanadium compound, and trimagnesium phosphate. The vanadium compound is a compound satisfying a predetermined electrical conductivity. The content of the vanadium compound is limited to a specified amount with respect to 100 mass % of the total of the coating film-forming resin solids and the cross-linking agent solids. The vanadium compound has a specified pH, and the content of the trimagnesium phosphate is a specified amount with respect to 100 mass % of the total of the coating film-forming resin solids and the cross-linking agent solids.

Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

Abstract: The present invention provides novel sulfonamide compounds having TRPM8 antagonistic activity which are useful as medicaments. Specifically, the present invention provides a sulfonamide compound of the formula (I): wherein Ring A is the following formula (i), (ii), or (ix): R4 is optionally substituted alkyl, X1 and X2 are each independently tetrazolyl, tetrazolinonyl, optionally substituted triazolyl, triazolinonyl, oxadiazolonyl, optionally substituted alkanoylaminomethyl, or optionally substituted alkylsulfonylaminomethyl, or R4 and X2 combine with each other at their terminals together with the adjacent benzene to form indazolinonyl or benzoisoxazolonyl, and the other symbols are the same as described in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides novel sulfonamide compounds having TRPM8 antagonistic activity which are useful as medicaments. Specifically, the present invention provides a sulfonamide compound of the formula (I): wherein Ring A is the following formula (i), (ii), or (ix): R4 is optionally substituted alkyl, X1 and X2 are each independently tetrazolyl, tetrazolinonyl, optionally substituted triazolyl, triazolinonyl, oxadiazolonyl, optionally substituted alkanoylaminomethyl, or optionally substituted alkylsulfonylaminomethyl, or R4 and X2 combine with each other at their terminals together with the adjacent benzene to form indazolinonyl or benzoisoxazolonyl, and the other symbols are the same as described in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

Abstract: The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity.

Abstract: A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH2— group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl grou

Abstract: A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH2— group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl gro

Abstract: The present invention relates to a cationic electrodeposition coating composition comprising silica particles having pore volume of 0.44 to 1.8 ml/g and average particle size of no more than 10 ?m, the composition showing square root of diffusion coefficient (?Tc) of no less than 2.5 upon diffusing a solution onto a coating film therewith; a cationic electrodeposition coating composition comprising silica particles having pore volume of 0.44 to 1.8 ml/g and average particle size of no more than 10 ?m, wherein the composition shows minimum deposition pH of 11.90 to 12.00 during electrodeposition coating, and film resistance of 1,000 to 1,500 k?·cm2 at film thickness of 15 ?m and applied voltage of 240 V; and an article coated with such cationic electrodeposition coating composition.

Abstract: An optically active compound of formula (I): ##STR1## in which R.sup.3 represents groups of formula --A--COOR.sup.4, whereinA represents alkylene groups having 3 or 5 carbon atoms andR.sup.4 represents hydrogen or an alkyl group having 1 to 4 carbon atoms; or a pharmaceutically acceptable salt thereof.

Abstract: Thiazolidinecarboxylic acid amides having combined antiallergic and antiasthmatic activities with an antagonist activity against platelet Activating Factor and having the following general formula (I) ##STR1##